TFFP vs. ADXS, EVFM, NMTR, PTEIQ, CYTO, UPC, BIOR, BDRX, PRFX, and PXMD
Should you be buying TFF Pharmaceuticals stock or one of its competitors? The main competitors of TFF Pharmaceuticals include Ayala Pharmaceuticals (ADXS), Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), PolarityTE (PTEIQ), Altamira Therapeutics (CYTO), Universe Pharmaceuticals (UPC), Biora Therapeutics (BIOR), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
TFF Pharmaceuticals vs.
TFF Pharmaceuticals (NASDAQ:TFFP) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
TFF Pharmaceuticals received 67 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 67.68% of users gave TFF Pharmaceuticals an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
15.3% of TFF Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 4.5% of TFF Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
TFF Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. TFF Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
TFF Pharmaceuticals presently has a consensus target price of $44.00, suggesting a potential upside of 67,592.31%. Given TFF Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe TFF Pharmaceuticals is more favorable than Ayala Pharmaceuticals.
In the previous week, TFF Pharmaceuticals' average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.
TFF Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Ayala Pharmaceuticals has a net margin of 0.00% compared to TFF Pharmaceuticals' net margin of -1,596.64%. Ayala Pharmaceuticals' return on equity of 0.00% beat TFF Pharmaceuticals' return on equity.
Summary
TFF Pharmaceuticals beats Ayala Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get TFF Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TFF Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:TFFP) was last updated on 1/21/2025 by MarketBeat.com Staff
